High expression of HO-1 predicts poor prognosis of ovarian cancer patients and promotes proliferation and aggressiveness of ovarian cancer cells
- 163 Downloads
HO-1 has been proved to be associated with tumor aggressivity and poor prognosis in various cancers. Our study provides the first study to demonstrate the relationship of HO-1 expression and clinical characteristics in ovarian cancer patients.
Immunohistochemistry and western blotting were used to examine the expression of HO-1 in tissue species and fresh tissues. CCK-8 was used to investigate cell viability. Transwell chamber was performed to estimate migration and invasion capacities in A2780 and Skov-3 cells.
Immunohistochemistry and western blotting showed that the expression of HO-1 was higher in ovarian cancer tissues than normal ovarian tissues. High expression of HO-1 was significantly associated with serous ovarian cancer, high FIGO stage, lymph node metastasis, and non-optimal debulking. Patients with high expression of HO-1 exhibited an unfavorable prognosis. In vitro inducing the expression of HO-1 promoted the proliferation and metastasis of A2780 and Skov-3 cells, with the increased expressions of mesenchymal marker (Vimentin), epithelial–mesenchymal transition-associated transcript factor (Zeb-1), anti-apoptotic protein (Bcl-2), and the decreased expressions of epithelial marker (Keratin) and pro-apoptotic protein (Bax). Meanwhile, after incubating A2780 and Skov-3 together with HO-1 inhibitor, above results could be reversed.
HO-1 might be a potential marker for prediction of ovarian cancer prognosis and a target for ovarian cancer treatment.
KeywordsHO-1 Ovarian cancer Metastasis Prognosis
This work was supported by grants from the Development and Reform commission Project of Shandong Province (26010104081103).
Compliance with ethical standards
Conflict of interest
The authors have declared that no conflict of interest exists.
Informed consent was obtained from all individual participants included in the study.
For this type of study, formal consent is not required.
- 9.Gandini NA, Fermento ME, Salomon DG, Obiol DJ, Andres NC, Zenklusen JC, et al. Heme oxygenase-1 expression in human gliomas and its correlation with poor prognosis in patients with astrocytoma. Tumour Biol J Int Soc Oncodev Biol Med. 2014;35(3):2803–15. doi: 10.1007/s13277-013-1373-z.CrossRefGoogle Scholar
- 12.Cheng CC, Guan SS, Yang HJ, Chang CC, Luo TY, Chang J, et al. Blocking heme oxygenase-1 by zinc protoporphyrin reduces tumor hypoxia-mediated VEGF release and inhibits tumor angiogenesis as a potential therapeutic agent against colorectal cancer. J Biomed Sci. 2016;23:18. doi: 10.1186/s12929-016-0219-6.CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Joung EJ, Li MH, Lee HG, Somparn N, Jung YS, Na HK, et al. Capsaicin induces heme oxygenase-1 expression in HepG2 cells via activation of PI3K-Nrf2 signaling: NAD(P)H:quinone oxidoreductase as a potential target. Antioxid Redox Signal. 2007;9(12):2087–98. doi: 10.1089/ars.2007.1827.CrossRefPubMedGoogle Scholar
- 29.Kocanova S, Buytaert E, Matroule JY, Piette J, Golab J, de Witte P, et al. Induction of heme-oxygenase 1 requires the p38MAPK and PI3K pathways and suppresses apoptotic cell death following hypericin-mediated photodynamic therapy. Apoptosis Int J Programm Cell Death. 2007;12(4):731–41. doi: 10.1007/s10495-006-0016-x.CrossRefGoogle Scholar